PMID- 23869534
OWN - NLM
STAT- MEDLINE
DCOM- 20150709
LR  - 20161018
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Linking)
VI  - 27
IP  - 5
DP  - 2013 Sep-Oct
TI  - Safety of spironolactone in dogs with chronic heart failure because of 
      degenerative valvular disease: a population-based, longitudinal study.
PG  - 1083-91
LID - 10.1111/jvim.12141 [doi]
AB  - BACKGROUND: Spironolactone treatment in humans is associated with an increased 
      risk of hyperkalemia and renal dysfunction. HYPOTHESIS: Dogs with cardiac disease 
      treated with spironolactone, in addition to conventional therapy, are not at 
      higher risk for adverse events (AEs) than those receiving solely conventional 
      therapy. ANIMALS: One hundred and ninety-six client-owned dogs with naturally 
      occurring myxomatous mitral valve disease. METHODS: Prospective, double-blinded 
      field study with dogs randomized to receive either spironolactone (2 mg/kg once a 
      day) or placebo in addition to conventional therapy (angiotensin-converting 
      enzyme inhibitor, plus furosemide and digoxin if needed). Safety was compared 
      between treatment groups, using the frequency of AEs, death caused by cardiac 
      disease, renal disease, or both, and variations in serum sodium, potassium, urea, 
      and creatinine concentrations. For the latter, population-specific reference 
      intervals were established and out of range values (ORV) analyzed. RESULTS: The 
      number of AEs was similar in the spironolactone and reference groups (188 and 
      208, respectively), when followed for median duration of 217 days (range 
      [2-1,333]). At each study time point, the percentage of dogs showing ORV was 
      similar between groups. There were a higher number of deaths because of cardiac 
      disease, renal disease or both in the reference group (30.7% versus 13.7%) (P = 
      .0043). CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with heart failure receiving 
      spironolactone in addition to conventional treatment are not at a higher risk for 
      AEs, death caused by cardiac disease, renal disease, or both, hyperkalemia, or 
      azotemia.
CI  - Copyright (c) 2013 by the American College of Veterinary Internal Medicine.
FAU - Lefebvre, H P
AU  - Lefebvre HP
AD  - INP, Ecole Nationale Veterinaire de Toulouse, Unite de Recherche Clinique & 
      Departement des Sciences Cliniques, Universite de Toulouse, Toulouse, France.
FAU - Ollivier, E
AU  - Ollivier E
FAU - Atkins, C E
AU  - Atkins CE
FAU - Combes, B
AU  - Combes B
FAU - Concordet, D
AU  - Concordet D
FAU - Kaltsatos, V
AU  - Kaltsatos V
FAU - Baduel, L
AU  - Baduel L
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130719
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Diuretics)
RN  - 27O7W4T232 (Spironolactone)
RN  - 73K4184T59 (Digoxin)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - S7UI8SM58A (Carnitine)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use
MH  - Animals
MH  - Carnitine/administration & dosage/therapeutic use
MH  - Digoxin/administration & dosage/therapeutic use
MH  - Diuretics/adverse effects/*therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Furosemide/administration & dosage/therapeutic use
MH  - Heart Failure/drug therapy/etiology/*veterinary
MH  - Heart Valve Diseases/complications/*veterinary
MH  - Longitudinal Studies
MH  - Spironolactone/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Aldosterone
OT  - Potassium
OT  - Reference interval
OT  - Renal function
EDAT- 2013/07/23 06:00
MHDA- 2015/07/15 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/07/24 00:00 [received]
PHST- 2013/04/10 00:00 [revised]
PHST- 2013/06/04 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1111/jvim.12141 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2013 Sep-Oct;27(5):1083-91. doi: 10.1111/jvim.12141. Epub 2013 
      Jul 19.